ArticleInternational journal of cardiology. Congenital heart disease2022
Off-label use of Lifetech KONAR-MF™ ventricular septal defect occluder for large patent ductus arteriosus closure in <6 kg infants.
Article in International journal of cardiology. Congenital heart disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Case Report: Percutaneous closure of patent ductus arteriosus with the KONAR-MF™ device: initial experience and results at 6 months in a tertiary center.Frontiers in pediatrics · 2026Article
- Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.Journal of the American Heart Association · 2025Article
- Transcatheter closure of patent ductus arteriosus in infants weighing less than 6 kilograms - a two-center experience. Technical considerations.Cardiology journal · 2025Article
- Editor's corner & issue at a glance.International journal of cardiology. Congenital heart disease · 2022Article
- Procedural outcome and safety of percutaneous patent ductus arteriosus occlusion in adults.Annals of pediatric cardiologyArticle
- Off-label use of KONAR-MF™ occluder for transcatheter closure of patent ductus arteriosus in unusual circumstances.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Device PDA closure is increasingly used in smaller patients. Major safety concerns remain when applied to <6 kg infants with large PDA and challenging anatomy. We aimed to report our experience with the new Konar-MF™ ventricular septal defect (VSD) occluder for transcatheter closure of large patent ductus arteriosus (PDA) in infants <6 kg. Methods: Infants <6 kg in whom PDA occlusion was attempted using the Konar-MF™ VSD occluder were analyzed to review procedural characteristics and outcomes. Prospective follow-up was achieved until August 2021. Results: A total of 9 implantations were performed in 7 infants [age: 5.3 ± 3.4 (1.7-10.1) months, weight: 4.1 ± 0.8 (2.9-5.8) kg]. All PDAs were large and short [minimal ductal diameter: 5.6 ± 1.0 (4.5-7.0) mm, ductal length: 4.3 ± 0.6 (3.5-5) mm]. Successful device implantation was achieved in all cases without major complication. Early device embolization occurred in 1 case with safe percutaneous device removal. Late percutaneous device retrieval was achieved 5 weeks after implantation because of symptomatic residual shunt. In both cases a second Konar-MF™ VSD occluder was implanted with excellent outcome. Over a median follow-up of 12 (6-25) months, 1 patient died from a device-unrelated cause; all remaining patients are asymptomatic, with complete occlusion and no delayed device-related complication. Conclusions: Transcatheter closure of large PDA using the Konar-MF™ VSD occluder appears to be feasible, effective and safe in <6 kg infants. This approach might be an alternative to surgical ligation in carefully selected infants, although that remains to be confirmed by extensive experience and long-term outcomes data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.